lydiathurstan.ifbbpro — Supported

Audited July 19, 2026 · Post from Jan 11, 2026

✅Supported

The BPC-157 + TB-500 injury repair stack concept is grounded in real preclinical science showing both peptides promote wound healing and tissue repair through complementary mechanisms (angiogenesis, fibroblast activation, ECM remodeling). BPC-157 specifically has active Phase 2 clinical trial support for hamstring strain repair, the strongest evidence available. However, the combination itself lacks human validation, and TB-500 specifically has zero human orthopaedic trials — only animal data. The stack is mechanistically plausible and preclinically supported, but claims of human efficacy would be overstated without acknowledging the evidence remains largely animal-model based.

Share this audit

One link — full verdict, every claim, and PubMed citations included.

peptiq.io/check/fa6083c1…

Shareable link includes the full verdict, claims, and PubMed citations.

Post captionshow

BPC + TB500 the injury repair stack to solve IT ALL! Let’s discuss what it really does and how they work. #bodybuilding #injury #nutritionist #peptides #bpc

Video transcript not captured. This audit used the caption only. For a fuller audit, run a new check and paste the spoken transcript.

Claim breakdown

3 claims

“BPC + TB500 form an injury repair stack.”

✅Supported

Two 2026 peer-reviewed narrative reviews from orthopaedic journals explicitly discuss BPC-157 and TB-500 together as wound-healing peptides that promote angiogenesis and tissue repair in preclinical models. The concept of combining them as an injury repair stack is mechanistically grounded, though human clinical evidence for the specific combination remains absent.

Supporting studies

“BPC-157 helps with injury repair.”

✅Supported

Multiple peer-reviewed studies and an active Phase 2 randomized clinical trial (NCT07437547) support BPC-157's role in injury repair. Preclinical evidence is consistent across rat models for tendon, ligament, and muscle healing (Gwyer et al. 2019; Seiwerth et al. 2021). A Phase 2 human trial for acute hamstring strain is currently recruiting, representing the strongest clinical evidence tier available for this peptide.

Supporting studies

“TB-500 helps with injury repair.”

⚠️Overstated

TB-500 shows promise in preclinical models for angiogenesis and tissue repair (documented in Rahman et al. 2026 and Mayfield et al. 2026), but the evidence is exclusively animal/in-vitro. Critically, Mayfield et al. (2026, Am J Sports Med) explicitly states 'human orthopaedic data are lacking' for TB-500, and both TB-4 and TB-500 remain banned in sports, raising regulatory and safety questions.

Supporting studies

Audit another post

Instagram, TikTok, X, Reddit, or paste text directly.

New audit

Track your protocols

Dosing, logging, and reminders in the app.

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error